Literature DB >> 22101943

Another road leads to HIF-1 activation: implications for prostate cancer progression.

Yao Dai1, Kyungmi Bae, Dietmar W Siemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22101943      PMCID： PMC3735083          DOI： 10.1038/aja.2011.163

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  10 in total

1.  A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Authors:  Pier Paolo Scaglioni; Thomas M Yung; Lu Fan Cai; Hediye Erdjument-Bromage; Andrew J Kaufman; Bhuvanesh Singh; Julie Teruya-Feldstein; Paul Tempst; Pier Paolo Pandolfi
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

2.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Authors:  Rosa Bernardi; Ilhem Guernah; David Jin; Silvia Grisendi; Andrea Alimonti; Julie Teruya-Feldstein; Carlos Cordon-Cardo; M Celeste Simon; Shahin Rafii; Pier Paolo Pandolfi
Journal:  Nature       Date:  2006-08-17       Impact factor: 49.962

3.  The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses.

Authors:  Yu-Ru Lee; Wei-Chien Yuan; Hsuan-Chung Ho; Chun-Hau Chen; Hsiu-Ming Shih; Ruey-Hwa Chen
Journal:  EMBO J       Date:  2010-04-13       Impact factor: 11.598

4.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.

Authors:  Paul Mak; Irwin Leav; Bryan Pursell; Donggoo Bae; Xiaofang Yang; Cherie A Taglienti; Lindsey M Gouvin; Vishva M Sharma; Arthur M Mercurio
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

Review 5.  Hypoxia-inducible factor-1 in human breast and prostate cancer.

Authors:  K S Kimbro; J W Simons
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

6.  A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.

Authors:  Wei-Chien Yuan; Yu-Ru Lee; Shiu-Feng Huang; Yu-Min Lin; Tzu-Yin Chen; Hsiang-Ching Chung; Chin-Hsien Tsai; Hsin-Yi Chen; Cheng-Ta Chiang; Chun-Kai Lai; Li-Ting Lu; Chun-Hau Chen; De-Leung Gu; Yeong-Shiau Pu; Yuh-Shan Jou; Kun Ping Lu; Pei-Wen Hsiao; Hsiu-Ming Shih; Ruey-Hwa Chen
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

7.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Authors:  Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker
Journal:  Lancet Oncol       Date:  2008-03-17       Impact factor: 41.316

8.  HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer.

Authors:  Christodoulos P Pipinikas; Nicholas D Carter; Catherine M Corbishley; Christiane D Fenske
Journal:  Biomarkers       Date:  2008-11       Impact factor: 2.658

9.  Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy.

Authors:  Judith Jans; Jessica H van Dijk; Susanne van Schelven; Petra van der Groep; Sofie H Willems; Trudy N Jonges; Paul J van Diest; J L H Ruud Bosch
Journal:  Urology       Date:  2009-10-24       Impact factor: 2.649

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.